<p>Budesonide is a medication used to help get active, mild to moderate <a href="https://www.withpower.com/clinical-trials/ulcerative-colitis">ulcerative colitis</a> under control.</p>

Uceris

Proteinuria, Asthma, Itching + 16 more

Treatment

20 Active Studies for Uceris

Treatment for

Proteinuria

What is Uceris

Budesonide

The Generic name of this drug

Treatment Summary

Budesonide is a type of steroid used to treat inflammation of the lungs and intestines. It is used to treat asthma, COPD, Crohn's disease, and ulcerative colitis. Budesonide was approved by the FDA in 1994 and is sold under brand names such as Pulmicort and Entocort.

Rhinocort

is the brand name

image of different drug pills on a surface

Uceris Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Rhinocort

Budesonide

1994

134

Effectiveness

How Uceris Affects Patients

Budesonide is a medication used to decrease inflammation in the respiratory and digestive systems. The amount of budesonide taken can vary greatly between patients and it is known to be a relatively safe drug. However, patients should be aware of the risk of increased cortisol levels in the body and suppressed adrenal glands when taking this drug.

How Uceris works in the body

Corticosteroids reduce inflammation by stopping blood vessels from widening and white blood cells from moving to the inflamed area. They also change how genes are expressed, which affects how cells behave. Corticosteroids reduce the body's ability to create inflammation-causing molecules and increase the production of anti-inflammatory molecules. At lower doses, corticosteroids reduce inflammation, and at higher doses, they suppress the immune system. When taken for a long time, corticosteroids can also raise sodium levels and lower potassium levels in the body.

When to interrupt dosage

The quantity of Uceris is contingent upon the diagnosed condition, including Vasomotor Rhinitis, Crohn's Disease and Chronic Obstructive Pulmonary Disease (COPD). The amount of dosage varies, as per the administration technique (e.g. Enema; Kit; Tablet - Rectal or Respiratory (inhalation)) detailed in the below table.

Condition

Dosage

Administration

Proteinuria

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule - Oral, Capsule, Powder - Respiratory (inhalation), Powder, Aerosol, metered, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Tablet, extended release - Oral, Tablet, extended release, Capsule, coated pellets - Oral, Powder - Nasal; Respiratory (inhalation), Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Enema; Kit; Tablet - Rectal, Enema; Kit; Tablet, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Cutaneous, Kit, Kit - Rectal, Aerosol, metered - Respiratory (inhalation), Capsule, delayed release - Oral, Tablet, orally disintegrating - Oral, Spray, metered - Nasal, Aerosol, metered - Nasal, Nasal, Capsule, delayed release, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, orally disintegrating, Patch - Cutaneous, Patch

Colitis, Collagenous

Nasal Polyps

Acute Coryza

Ulcerative Colitis

Nasal Congestion

Hypersensitivity

IGA Glomerulonephritis

Sinusitis

Crohn's Disease

Asthma

Crohn Disease

Itching

Skin Diseases

Chronic Obstructive Pulmonary Disease

Rhinitis, Vasomotor

Eosinophilic Esophagitis

Crohn Disease

maintenance therapy

Warnings

Uceris Contraindications

Condition

Risk Level

Notes

Asthma

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Status Asthmaticus

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Budesonide may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Budesonide may interact with Pulse Frequency

There are 20 known major drug interactions with Uceris.

Common Uceris Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with Abatacept.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Budesonide.

Abetimus

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with Abetimus.

Uceris Toxicity & Overdose Risk

Acute overdose of corticosteroids is not common, however taking too much for too long can lead to an overproduction of corticosteroids and damage to the adrenal glands. In the case of overdose, the amount of corticosteroids taken should be reduced. A 200mg oral dose is deadly for female mice, and 400mg for male mice.

Uceris Novel Uses: Which Conditions Have a Clinical Trial Featuring Uceris?

516 active studies are presently examining the potential of Uceris to combat Chronic Obstructive Pulmonary Disease (COPD), Ulcerative Colitis and Allergic Reactions.

Condition

Clinical Trials

Trial Phases

Asthma

81 Actively Recruiting

Phase 1, Phase 4, Early Phase 1, Not Applicable, Phase 2, Phase 3

Itching

3 Actively Recruiting

Phase 3, Not Applicable

Chronic Obstructive Pulmonary Disease

70 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Proteinuria

5 Actively Recruiting

Phase 2, Phase 3, Phase 4, Phase 1

IGA Glomerulonephritis

0 Actively Recruiting

Ulcerative Colitis

17 Actively Recruiting

Phase 3, Phase 2, Phase 1, Not Applicable, Phase 4

Sinusitis

0 Actively Recruiting

Crohn's Disease

53 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1

Hypersensitivity

1 Actively Recruiting

Phase 4

Colitis, Collagenous

0 Actively Recruiting

Skin Diseases

0 Actively Recruiting

maintenance therapy

0 Actively Recruiting

Rhinitis, Vasomotor

1 Actively Recruiting

Not Applicable

Eosinophilic Esophagitis

0 Actively Recruiting

Acute Coryza

0 Actively Recruiting

Crohn Disease

0 Actively Recruiting

Nasal Polyps

0 Actively Recruiting

Crohn Disease

0 Actively Recruiting

Nasal Congestion

0 Actively Recruiting

Uceris Reviews: What are patients saying about Uceris?

Patient Review

7/1/2014

Uceris for Ulcerated Colon

I was on Balsalaszide and it wasn't helping me, so my doctor put me on Uceris. The results were amazing! I went from four bloody diarrhea stools to just one within a day, and now my stools are pretty normal. I'm very happy with this treatment.

Patient Review

6/11/2018

Uceris for Ulcerated Colon

After a few weeks, my face became puffy and I had an increased heart rate.

4.3

Patient Review

8/19/2014

Uceris for Ulcerated Colon

Overall, this treatment has been great for my colitis. I'm glad that insurance covers it because it's really expensive. The constant urination is a bit annoying, but it's better than going to the bathroom every time I eat something.

Patient Review

11/24/2013

Uceris for Ulcerated Colon

Patient Review

5/16/2014

Uceris for Ulcerated Colon

This has been a literal life-saver for my son who was diagnosed with Refractory Celiac Disease and Lymphocitic Colitis. Many other medications have failed where this one succeeded in reducing pain, frequency of bathroom trips, and ultimately allowed him to return to school!

1.7

Patient Review

4/21/2016

Uceris for Ulcerated Colon

Uceris did not help me manage my colitis flare-up as advertised. If anything, it made the symptoms worse. I stopped taking it as soon as possible and Prednisone provided relief almost immediately.

Patient Review

7/10/2018

Uceris for Ulcerated Colon

I had a lot of negative side effects from this medication, including pain, loss of appetite, and more trips to the bathroom with blood in my stool. I'm glad it works for some people, but it definitely wasn't the right fit for me.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about uceris

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Uceris weaken your immune system?

"If you take UCERIS tablets, it may weaken your immune system. This means that you are more likely to get infections. To avoid getting sick, stay away from people who have contagious diseases like chickenpox or measles."

Answered by AI

Is Uceris a steroid?

"Budesonide is a medication used to help get active, mild to moderate ulcerative colitis under control."

Answered by AI

What are the side effects of Uceris?

"The following are some possible side effects: headache, dizziness, indigestion, nausea, vomiting, stomach pain, bloating, gas, constipation, feeling tired, back pain, joint pain, painful urination, cold symptoms such as stuffy nose, sneezing, sore throat, or pain anywhere in your body."

Answered by AI

How long does it take for Uceris to work?

"The second, more bothersome side effect, was fatigue.

It took about two weeks for the medication to take effect and my diarrhea to stop completely. I had two side effects: swelling in both ankles that lasted for a few days, and fatigue, which was more bothersome."

Answered by AI

Clinical Trials for Uceris

Have you considered Uceris clinical trials?

We made a collection of clinical trials featuring Uceris, we think they might fit your search criteria.

Have you considered Uceris clinical trials?

We made a collection of clinical trials featuring Uceris, we think they might fit your search criteria.

Image of Johns Hopkins University School of Medicine in Baltimore, United States.

N-Acetylglucosamine for Crohn's Disease

18 - 80

All Sexes

Baltimore, MD

Protein glycosylation is a critical post-translational modification that regulates protein trafficking and protein-protein interactions impacting a host of physiological processes. There is a growing appreciation of glycosylation defects in chronic human diseases, including Crohns disease. Crohns disease (CD), and the related condition of ulcerative colitis, are chronic inflammatory bowel diseases (IBD) that impact 3.1 million Americans. While the development of medications has revolutionized care of CD patients, clinical remission is only achieved in \~40% of patients a therapeutic ceiling that has not changed in 20 years. These data underscore the need for new CD treatment strategies. The investigators are focused on understanding the role of defective N-glycosylation in CD, as an innovative strategy to identify and develop new therapeutics. Depending on ancestral background, 7-25% of CD patients carry a pathogenic, missense mutation in the manganese (Mn) transporter ZIP8 (rs13107325; ZIP8 A391T). ZIP8 regulates systemic Mn homeostasis with ZIP8 391-Thr causing a relative Mn insufficiency. Mn is a required metal cofactor for enzymes regulating key cellular processes, like N-glycosylation. In the gut, protein N-glycosylation plays key roles in host-pathogen interactions, inflammation, and cell-cell interactions. The investigator's central hypothesis is that in patients carrying ZIP8 391-Thr - CD is exacerbated by aberrant N-glycosylation and that this defect can be targeted by specific, safe therapy. Supporting this hypothesis, Mn levels are reduced (\~15%) in ZIP8 391-Thr allele carriers and this is associated with a decrease in complex N-glycan branching in plasma. Further, the investigators uncovered a microbiota signature in the ileal mucosa that implicated altered bile acid homeostasis in ZIP8 391-Thr carriers. To better understand CD in ZIP8 391 carriers, the investigators generated a knock-in mouse model of ZIP8 391-Thr (Zip8393T/393T). Like patient data, the investigators observe reduced branching of N-glycans and disrupted bile acid homeostasis in the Zip8393T/393T mice. Promising human trials have shown that defects in N-glycan branching can be safely restored by raising levels of the rate-limiting metabolite UDP-N-acetylglucosamine (GlcNAc) via supplementation with free GlcNAc. The investigator's preliminary data in Zip8393T/393T mice have demonstrated that GlcNAc supplementation restores N-glycan branching deficits, rescues the defect in bile acid homeostasis, and ameliorates colitis susceptibility. Thus, the objective of the proposed research is to test a safe and effective therapy for patients carrying ZIP8 391-Thr and others who may have underlying changes in N-glycosylation. The investigators will perform a multi-center, randomized, double-blind, placebo-controlled cross-over study to test the safety and tolerability of oral GlcNAc as a proof-of-concept study. The investigators will use two cohorts stratified by ZIP8 391-Thr genotype status (carriers and non-carriers, n= 20 participants in each cohort, total= 40 participants).

Phase 2

Waitlist Available

Has No Placebo

Johns Hopkins University School of Medicine

Joanna Melia, MD

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+

All Sexes

Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available

Has No Placebo

Stanford University

Jeff Swigris, DO, MS

Minnesota Health Solutions